Julian F Guest

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7258365/publications.pdf

Version: 2024-02-01

430874 233421 2,096 52 18 45 h-index citations g-index papers 53 53 53 2060 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Health economic burden that wounds impose on the National Health Service in the UK. BMJ Open, 2015, 5, e009283.	1.9	445
2	Health economic burden that different wound types impose on the <scp>UK</scp> 's National Health Service. International Wound Journal, 2017, 14, 322-330.	2.9	301
3	Cohort study evaluating the burden of wounds to the UK's National Health Service in 2017/2018: update from 2012/2013. BMJ Open, 2020, 10, e045253.	1.9	218
4	Venous leg ulcer management in clinical practice in the UK: costs and outcomes. International Wound Journal, 2018, 15, 29-37.	2.9	138
5	Health economic impact of managing patients following a community-based diagnosis of malnutrition in the UK. Clinical Nutrition, 2011, 30, 422-429.	5.0	124
6	Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes. International Wound Journal, 2018, 15, 43-52.	2.9	85
7	Cohort study evaluating pressure ulcer management in clinical practice in the UK following initial presentation in the community: costs and outcomes. BMJ Open, 2018, 8, e021769.	1.9	74
8	Clinical Outcomes and Cost-effectiveness of Continuous Positive Airway Pressure to Manage Obstructive Sleep Apnea in Patients With Type 2 Diabetes in the U.K Diabetes Care, 2014, 37, 1263-1271.	8.6	64
9	Modelling the annual NHS costs and outcomes attributable to healthcare-associated infections in England. BMJ Open, 2020, 10, e033367.	1.9	62
10	Healthcare costs and outcomes of managing βâ€ŧhalassemia major over 50 years in the United Kingdom. Transfusion, 2016, 56, 1038-1045.	1.6	49
11	Modeling the Cost-Effectiveness of Prothrombin Complex Concentrate Compared With Fresh Frozen Plasma in Emergency Warfarin Reversal in the United Kingdom. Clinical Therapeutics, 2010, 32, 2478-2493.	2.5	47
12	Modelling the cost-utility of bioâ€'electric stimulation therapy compared to standard care in the treatment of elderly patients with chronic non-healing wounds in the UK. Current Medical Research and Opinion, 2007, 23, 871-883.	1.9	42
13	Costâ€effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as firstâ€line treatment for cow milk allergy in the UK. Pediatric Allergy and Immunology, 2012, 23, 240-249.	2.6	36
14	Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK. Current Medical Research and Opinion, 2008, 24, 1841-1852.	1.9	27
15	Costs and outcomes in evaluating management of unhealed surgical wounds in the community in clinical practice in the UK: a cohort study. BMJ Open, 2018, 8, e022591.	1.9	23
16	Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis. PLoS ONE, 2017, 12, e0187792.	2.5	22
17	Modelling the costs and consequences of reducing healthcare-associated infections by improving hand hygiene in an average hospital in England. BMJ Open, 2019, 9, e029971.	1.9	21
18	Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Health and Quality of Life Outcomes, 2015, 13, 24.	2.4	20

#	Article	IF	CITATIONS
19	Budget impact of managing cow milk allergy in the Netherlands. Journal of Medical Economics, 2010, 13, 273-283.	2.1	18
20	Modelling the resource implications and budget impact of new reimbursement guidelines for the management of cow milk allergy in Finland. Current Medical Research and Opinion, 2008, 24, 1167-1177.	1.9	17
21	Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK. European Journal of Health Economics, 2017, 18, 761-771.	2.8	16
22	Effectiveness of using an extensively hydrolyzed casein formula supplemented with <i>Lactobacillus rhamnosus</i> GG compared with an extensively hydrolysed whey formula in managing cow's milk protein allergic infants. Journal of Comparative Effectiveness Research, 2019, 8, 1317-1326.	1.4	16
23	Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom. Sarcoma, 2013, 2013, 1-9.	1.3	14
24	Relative cost-effectiveness of using an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in Spain. ClinicoEconomics and Outcomes Research, 2015, 7, 583.	1.9	14
25	Cohort study evaluating management of burns in the community in clinical practice in the UK: costs and outcomes. BMJ Open, 2020, 10, e035345.	1.9	14
26	Relative cost-effectiveness of an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in Italy. ClinicoEconomics and Outcomes Research, 2015, 7, 325.	1.9	13
27	Relative cost-effectiveness of using an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in Poland. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 307-316.	1.9	13
28	Modelling the health economic impact of managing cow milk allergy in South Africa. Journal of Medical Economics, 2010, 13, 257-272.	2.1	12
29	Cost Effectiveness of Establishing a Neonatal Screening Programme for Phenylketonuria in Libya. Applied Health Economics and Health Policy, 2010, 8, 407-420.	2.1	11
30	Potential cost-effectiveness of using a collagen-containing dressing in managing diabetic foot ulcers in the UK. Journal of Wound Care, 2018, 27, 136-144.	1.2	11
31	Cost-effectiveness of an electroceutical device in treating non-healing venous leg ulcers: results of an RCT. Journal of Wound Care, 2018, 27, 230-243.	1.2	10
32	Modelling the resource implications of managing adults with Fabry disease in Italy. European Journal of Clinical Investigation, 2011, 41, 710-718.	3.4	9
33	Cost implications of post-surgical morbidity following blood transfusion in cancer patients undergoing elective colorectal resection: an evaluation in the US hospital setting. Current Medical Research and Opinion, 2005, 21, 447-455.	1.9	8
34	Cost-effectiveness of using an extensively hydrolyzed casein formula supplemented with ⟨i>Lactobacillus rhamnosus⟨/i> GG in managing IgE-mediated cow's milk protein allergy in the UK. Current Medical Research and Opinion, 2019, 35, 1677-1685.	1.9	8
35	Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. European Journal of Clinical Investigation, 2010, 40, 1104-1112.	3.4	7
36	Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leukemia and Lymphoma, 2012, 53, 928-933.	1.3	7

#	Article	IF	CITATIONS
37	Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden. Sarcoma, 2013, 2013, 1-19.	1.3	7
38	Cost-effectiveness of using a collagen-containing dressing plus compression therapy in non-healing venous leg ulcers. Journal of Wound Care, 2018, 27, 68-78.	1.2	7
39	Cost-effectiveness of using an extensively hydrolyzed casein formula containing <i>Lactobacillus rhamnosus</i> GG in managing infants with cow's milk allergy in the US. Current Medical Research and Opinion, 2018, 34, 1539-1548.	1.9	7
40	<p>Cost-Effectiveness and Cost-Benefit of Cervical Cancer Screening with Liquid Based Cytology Compared with Conventional Cytology in Germany</p> . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 153-166.	1.9	7
41	Cost-effectiveness of using an extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus GG compared to an extensively hydrolyzed formula alone or an amino acid formula as first-line dietary management for cow's milk allergy in the US. ClinicoEconomics and Outcomes Research, 2015, 7, 145.	1.9	6
42	Cost-effectiveness of Debrichem in managing hard-to-heal venous leg ulcers in the UK. Journal of Wound Care, 2022, 31, 480-491.	1.2	6
43	Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom. Leukemia and Lymphoma, 2014, 55, 1870-1875.	1.3	5
44	Utility values for specific hepatic encephalopathy health states elicited from the general public in the United Kingdom. Health and Quality of Life Outcomes, 2014, 12, 89.	2.4	5
45	Potential costâ€effectiveness of using adjunctive dehydrated human amnion/chorion membrane allograft in the management of nonâ€healing diabetic foot ulcers in the United Kingdom. International Wound Journal, 2021, 18, 889-901.	2.9	5
46	Cost-effectiveness of using intermittent pneumatic compression to manage hard-to-heal venous leg ulcers in the UK. Journal of Wound Care, 2021, 30, 544-552.	1.2	5
47	Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. Clinical Therapeutics, 2009, 31, 2398-2415.	2.5	4
48	Costâ€effectiveness of using Polyheal compared with surgery in the management of chronic wounds with exposed bones and/or tendons due to trauma in France, Germany and the <scp>UK</scp> . International Wound Journal, 2015, 12, 70-82.	2.9	4
49	Relative cost-effectiveness of using an extensively hydrolyzed casein formula in managing infants with cow's milk allergy in Brazil. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 629-639.	1.9	4
50	Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom. PLoS ONE, 2018, 13, e0191945.	2.5	4
51	Relative cost-effectiveness of using a liquid human milk fortifier in preterm infants in the US. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 49-57.	1.9	3
52	Response to Comment on Guest et al. Clinical Outcomes and Cost-effectiveness of Continuous Positive Airway Pressure to Manage Obstructive Sleep Apnea in Patients With Type 2 Diabetes in the U.K. Diabetes Care 2014;37:1263–1271. Diabetes Care, 2014, 37, e202-e203.	8.6	1